Functional genomic screens and identification of signaling pathways in oxaliplatin-resistance in colorectal cancer.
Niharika B. Mettu(Duke Medical Center), Shiaowen David Hsu(Duke Medical Center), Joshua M. Uronis(University of North Carolina at Chapel Hill), Min Lu(Vanderbilt University), Kris C. Wood(Duke University), Michael A. Morse(Duke Medical Center), Takuya Osada(Rakuten (Japan)), Wei Chen(Jiangnan University), H. Kim Lyerly(Duke University), Robert Mook(Duke Medical Center), Koya Osada(Duke University)
Cited by 0
Related Papers
Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study
|The Lancet Oncology|2017|2.8k
Metabolic programming and PDHK1 control CD4+ T cell subsets and inflammation
|Journal of Clinical Investigation|2014|717
NCCN Task Force Report: Management of Patients with Gastrointestinal Stromal Tumor (GIST)—Update of the NCCN Clinical Practice Guidelines
|Journal of the National Comprehensive Cancer Network|2007|636